Efficacy and Safety of Mirikizumab for Induction and Maintenance of Remission in Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Objective: Mirikizumab, a p19-directed anti-interleukin-23 monoclonal antibody, has been evaluated as induction and maintenance therapy for moderately to severely active ulcerative colitis (UC). We conducted a systematic review and meta-analysis of randomized, placebo-controlled trials to quantify its efficacy and safe...